Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study

Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial.

(2017) Robert R. McWilliams et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Small bowel adenocarcinomas—existing evidence and evolving paradigms

(2013) Kanwal Raghav et al.   Nature Reviews Clinical Oncology

A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma

(2012) Xiao Jun Xiang et al.   ANTI-CANCER DRUGS

CpG Island Methylator Phenotype-Positive Tumors in the Absence of MLH1 Methylation Constitute a Distinct Subset of Duodenal Adenocarcinomas and Are Associated with Poor Prognosis

(2012) T. Fu et al.   CLINICAL CANCER RESEARCH

A Population-Based Comparison of Adenocarcinoma of the Large and Small Intestine: Insights Into a Rare Disease

(2011) Michael J. Overman et al.   ANNALS OF SURGICAL ONCOLOGY

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2011) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine

(2009) M J Overman et al.   BRITISH JOURNAL OF CANCER

Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater

(2009) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY